Navigation Links
Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference

Potent synergy, activity and patient tolerance observed in Genotype 1 patients support development of Omega DUROS(R) continuous delivery therapy

WASHINGTON, May 21, 2007 /PRNewswire/ -- Intarcia Therapeutics, Inc., a privately held biopharmaceutical company, today announced the presentation of final results from a Phase 2 study comparing the combination of injectable omega interferon and ribavirin to omega interferon alone in treatment-naive patients with genotype 1 chronic hepatitis C. The results demonstrate that omega interferon in combination with ribavirin is well tolerated and shows robust antiviral activity that is comparable to published data on the use of alpha interferon plus ribavirin in similar patient populations. The 72-week sustained viral response (SVR) data are being presented today at the Digestive Disease Week Conference in Washington, DC by Bruce R. Bacon, MD, Professor of Internal Medicine, Saint Louis University Medical Center, St. Louis, Missouri.

This Phase 2 study of daily subcutaneous omega interferon injections provides Intarcia with safety and clinical response data to support development of omega interferon delivered by continuous release from the DUROS(R) device.

"The safety and SVR rates achieved in this phase 2 study are encouraging in that they indicate that the combination of omega interferon and ribavirin may produce response rates which are similar to those achieved with alpha interferon and ribavirin in patients with HCV genotype-1," said Dr. Bacon. "The positive results of this study allow us to proceed with the evaluation of continuous delivery of omega interferon delivered with the DUROS device. A trial evaluating dose response of the Omega DUROS device is expected to begin in the near future."

The Phase 2 trial compared the safety and antiviral response of omega interferon alone with omega interferon in combination with ribavirin in 102 interferon-na
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:7/11/2014)... 11, 2014 According to ... Composition of Material, Application (Healthcare, Homeland security, Industrial ... (Personal Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) ... 2013 - 2020", published by MarketsandMarkets, the Scintillator Market is ... from 2014 to 2020, and reach $479.16 Million ...
(Date:7/11/2014)... 11, 2014  Australian drug delivery company, Phosphagenics Limited ... raised A$19.3 million via a placement of A$16.3 million ... the U.S., Asia and ... share purchase plan (SPP) to be offered to existing ... in two tranches. "This capital raising positions ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Nov. 1, 2010 The National Quality Forum ... of its eight member councils.   ... to improving the quality of American healthcare by ... endorsing national consensus standards for measuring and publicly ...
... Octapharma AG , one of ... and Octapharma USA today announced that patients ... a multi-center study that is researching the use of ... human cell line (Human-cl rhFVIII). Researchers are investigating Human-cl ...
Cached Medicine Technology:National Quality Forum Members Elect New Council Leaders 2Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line 2Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line 3
(Date:7/13/2014)... 2014 Athletes with a certain genetic ... concussions, according to research presented today at the American ... Meeting. The research marks the first of its kind ... known physical events that occur after a head injury. ... allele in the (GT)n genotype were four times more ...
(Date:7/13/2014)... Rico (PRWEB) July 13, 2014 ... of Famer, Chris Mullin, will be the featured guest ... July 26th in Puerto Rico. Attendees will learn ... will participate in two exhibition basketball games and perform ... ultimate supplier of health- and energy-boosting supplements , ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Epidemiologists forecast ... in the 6MM, from 8,062 diagnosed incident cases in ... an Annual Growth Rate (AGR) of 4.35%, during the ... highest number of diagnosed incident cases of aGVHD in ... will have the lowest number of diagnosed incident cases ...
(Date:7/13/2014)... According to the Kidney Disease Solution book ... step guide on what to do to eliminate the root ... writes in its review that readers can easily learn what ... their kidney health. Vkool also informs in its Kidney Disease ... damaged kidney functions naturally. The book consists of a collection ...
(Date:7/13/2014)... Beverly Hills, California (PRWEB) July 13, 2014 ... Champion Danny Musico has formed a promotional partnership with ... revolutionary plant based Omega-3 EPA supplement . The ... Musico is a celebrity fitness trainer , actor, ... As Hollywood’s go-to trainer for A-List celebrities, he has ...
Breaking Medicine News(10 mins):Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... 2 Hess Corporation will present two $50,000 checks -- one ... other to Children,s Hospital Boston,s Trauma Program -- as part of ... opening day. Aric Morrison, a Hess Retail regional director, will present ... promised to donate $500 for every home run hit during a ...
... in ongoing program to prevent adverse health events ... Thirty-one Minnesota hospitals recently were named winners of the ... awards honor hospitals, efforts to prevent four types of ... invasive procedures and foreign objects retained during labor and ...
... CHICAGO, Oct. 2 Beginning October 1st, The Peninsula Chicago ... Cancer Awareness Month and several cancer research and education organizations. ... by breast cancer in some way and this is why ... said Maria Zec, general manager of The Peninsula Chicago. "In ...
... devastation of the 1918-1919 influenza pandemic is well known, but ... death toll: the misuse of aspirin. Appearing in the November ... the article sounds a cautionary note as present day concerns ... dosing levels used to treat patients during the 1918-1919 pandemic ...
... more improves outcomes, study shows , FRIDAY, Oct. 2 ... bypass surgery can be used to reverse morbid obesity ... U.S. researchers say. , Their study included 61 teens ... Hospital Medical Center. One year after surgery, overall body ...
... lead to better treatments, researchers say, , FRIDAY, Oct. ... stomach cancers could lead to more effective treatments and ... say. , For a study published online Oct. 1 ... stomach tumors from people in Australia, Singapore and Great ...
Cached Medicine News:Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 3Health News:Thirty-one Minnesota Hospitals Win Patient Safety Awards 2Health News:The Peninsula Chicago Gives Back During Breast Cancer Awareness Month 2Health News:Delaying Weight-Loss Surgery May Leave Teens at Risk 2Health News:New Classification Proposed for Stomach Cancers 2
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
... Macula Plus® 5.5 is ... of the optic nerve ... it with your binocular ... choroidal neovascular membranes, macular ...
The Professional ophthalmoscope has been designed to ensure ultimate control. Lenses, graticules and filters can all be introduced at the touch of a fingertip without the need to pull away from the p...
The iQ200 Automated Urinalysis System (iQ System) is a user-friendly, bench top, fully automated system that performs complete urinalyses on unspun specimens; simply load, press START and walk away....
Medicine Products: